Vyvanse (Lisdexamfetamine) is a psychostimulant medication that was developed by the company Shire. It is primarily prescribed for the treatment of ADHD (attention deficit hyperactivity disorder) and works well to improve cognitive function. In addition to treating ADHD, many doctors have used the drug to help individuals with excessive daytime sleepiness and binge eating disorders. …
Adderall is arguably the single most popular psychostimulant medication on the market. In addition to being a highly effective treatment option for ADHD (attention-deficit hyperactivity disorder), it is also sometimes used to treat narcolepsy, and as an antidepressant augmentation strategy. Many doctors don’t mind prescribing this drug to patients with non-addictive personalities because it has been …
Dopamine Reuptake Inhibitors (DRIs) are drugs that function by preventing the reuptake of the neurotransmitter dopamine. The fact that they prevent dopamine reuptake leads to increased concentrations of dopamine between synapses. This increases stimulation of the central nervous system and tends to improve cognitive function, alertness, and performance. These medications are most often utilized for …
Norepinephrine Dopamine Reuptake Inhibitors (NDRIs) are drugs that function by inhibiting the reuptake of the neurotransmitters norepinephrine and dopamine. This leads to increased neural concentrations of these activating neurotransmitters, resulting in increased stimulation of the central nervous system. Certain NDRIs inhibit reuptake of norepinephrine to a greater extent than dopamine (and vice versa). Others may have …
Reward deficiency syndrome (RDS) is a psychological theory first noted by Kenneth Blum in 1996. It is characterized by reward-seeking behavior and/or addictions, stemming from genetic variations, most notably resulting from those carrying the D2A1 allele. People carrying the A1 allele tend to have insufficient numbers of D2 receptors in their brain, resulting in lack …
There is a newer class of antidepressant drugs called Triple Reuptake Inhibitors (TRI’s or SNDRI drugs) being developed that target all major neurotransmitters involved in depression: serotonin, norepinephrine, and dopamine. The thought process behind the creation of this new class of triple reuptake inhibitors is that they will target all three major neurotransmitters that are thought …
Based on the symptoms experienced as a result of lower levels of dopamine, it is thought that dopamine plays just as big of a role as serotonin in treating depression. Why then are medications used to treat depression primarily dealing with targeting serotonin only? Because people have been brainwashed by pharmaceutical companies? Maybe. It could …